JP2024503091A5 - - Google Patents

Info

Publication number
JP2024503091A5
JP2024503091A5 JP2023542960A JP2023542960A JP2024503091A5 JP 2024503091 A5 JP2024503091 A5 JP 2024503091A5 JP 2023542960 A JP2023542960 A JP 2023542960A JP 2023542960 A JP2023542960 A JP 2023542960A JP 2024503091 A5 JP2024503091 A5 JP 2024503091A5
Authority
JP
Japan
Prior art keywords
aav vector
seq
nucleic acid
capsid protein
recombinant aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023542960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503091A (ja
JP7895046B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012542 external-priority patent/WO2022155482A1/en
Publication of JP2024503091A publication Critical patent/JP2024503091A/ja
Publication of JP2024503091A5 publication Critical patent/JP2024503091A5/ja
Application granted granted Critical
Publication of JP7895046B2 publication Critical patent/JP7895046B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023542960A 2021-01-14 2022-01-14 T細胞を標的とするaavベクター Active JP7895046B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137497P 2021-01-14 2021-01-14
US63/137,497 2021-01-14
PCT/US2022/012542 WO2022155482A1 (en) 2021-01-14 2022-01-14 Aav vectors targeting t-cells

Publications (3)

Publication Number Publication Date
JP2024503091A JP2024503091A (ja) 2024-01-24
JP2024503091A5 true JP2024503091A5 (cg-RX-API-DMAC7.html) 2025-01-22
JP7895046B2 JP7895046B2 (ja) 2026-07-27

Family

ID=81328090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542960A Active JP7895046B2 (ja) 2021-01-14 2022-01-14 T細胞を標的とするaavベクター

Country Status (10)

Country Link
US (1) US20240123085A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277920A1 (cg-RX-API-DMAC7.html)
JP (1) JP7895046B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230135093A (cg-RX-API-DMAC7.html)
CN (1) CN117203222A (cg-RX-API-DMAC7.html)
AR (1) AR124651A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022208037A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204794A1 (cg-RX-API-DMAC7.html)
TW (1) TW202242124A (cg-RX-API-DMAC7.html)
WO (1) WO2022155482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2025179007A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California Adeno-associated virus compositions and methods of use thereof for human cells
WO2026098570A1 (en) * 2024-11-06 2026-05-15 Westlake Genetech. Ltd. Adeno-associated virus variants and uses in t cell engineering

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7966987A (en) 1986-09-08 1988-04-07 Applied Biotechnology, Inc. Empty viral capsid vaccines
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
US5916563A (en) 1988-11-14 1999-06-29 United States Of America Parvovirus protein presenting capsids
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ES2026826A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
EP0883344B2 (en) 1995-12-15 2010-06-09 VIRxSYS Corporation Therapeutic molecules generated by trans-splicing
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
AU774706B2 (en) 1998-09-22 2004-07-08 Johns Hopkins University, The Methods for large-scale production of recombinant AAV vectors
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
US6623729B2 (en) 2001-07-09 2003-09-23 Korea Advanced Institute Of Science And Technology Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
US7071172B2 (en) 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
JP4346526B2 (ja) 2004-08-31 2009-10-21 株式会社東芝 半導体集積回路装置
CA2579519A1 (en) 2004-09-09 2006-03-16 The General Hospital Corporation Modulating phosphatase activity in cardiac cells
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
US8283151B2 (en) * 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
AU2006242371A1 (en) 2005-04-29 2006-11-09 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
JP2009525757A (ja) 2006-02-10 2009-07-16 ザ ユニバーシティ オブ シンシナティ 心機能のレギュレータとしてのホスファターゼインヒビタープロテイン−1
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2940131B1 (en) * 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
SG11201901757YA (en) * 2016-09-08 2019-03-28 Bluebird Bio Inc Pd-1 homing endonuclease variants, compositions, and methods of use
JP2020510424A (ja) 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 改変aavカプシドおよびその使用
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
US20240366788A1 (en) * 2021-07-23 2024-11-07 Duke University Adeno-associated virus compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP2023544683A5 (cg-RX-API-DMAC7.html)
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
JP2024178382A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2022527199A5 (cg-RX-API-DMAC7.html)
JP2023506765A5 (cg-RX-API-DMAC7.html)
JP2023179436A5 (cg-RX-API-DMAC7.html)
JP2022507454A5 (cg-RX-API-DMAC7.html)
JP2021521833A5 (cg-RX-API-DMAC7.html)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2020508685A5 (cg-RX-API-DMAC7.html)
JP2023504773A5 (cg-RX-API-DMAC7.html)
JP2025184979A5 (cg-RX-API-DMAC7.html)
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2010516758A5 (cg-RX-API-DMAC7.html)
JP2020518268A5 (cg-RX-API-DMAC7.html)
JP2023524291A5 (cg-RX-API-DMAC7.html)
JP2025515503A5 (cg-RX-API-DMAC7.html)
JP2022513459A5 (cg-RX-API-DMAC7.html)
JPWO2020218419A5 (cg-RX-API-DMAC7.html)
JP2023554379A5 (cg-RX-API-DMAC7.html)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2025516638A5 (cg-RX-API-DMAC7.html)
JP2024523394A5 (cg-RX-API-DMAC7.html)